Skip to main content
Top
Published in:

26-07-2023 | Duodenal Stenosis | Case Report - Immunotherapy

A pathological complete response after immunotherapy with pembrolizumab for distal duodenal adenocarcinoma caused by Lynch syndrome: a case report

Authors: Shinichiro Ikeda, Qingjiang Hu, Keita Natsugoe, Tomoya Harima, Yasushi Tanaka, Izumi Kinoshita, Kentaro Nonaka, Sho Nambara, Ryota Nakanishi, Tomonori Nakanoko, Mitsuhiko Ota, Yasue Kimura, Eiji Oki, Yoshinao Oda, Tomoharu Yoshizumi

Published in: International Cancer Conference Journal | Issue 4/2023

Login to get access

Abstract

Primary adenocarcinoma of the duodenum is a rare neoplasm that is often microsatellite instability-high (MSI-H). Pembrolizumab, a monoclonal antibody, has been recently approved in Japan for treatment of MSI-H solid tumors. Lynch syndrome is a frequent hereditary cancer predisposition syndrome. It is linked to an increased risk of various types of cancer, including colorectal and endometrial cancer, and is closely related to MSI-H. We present the case of a 55-year-old woman who was diagnosed with duodenal cancer. Biopsy findings revealed MSI-H, and pembrolizumab therapy was initiated because the tumor was in contact with the left renal vein and had metastasized to the mesenteric lymph nodes of the small intestine. Subsequently, after completing two courses of pembrolizumab therapy, the patient developed duodenal stenosis and underwent surgery. Pathological analysis of the resected specimen revealed no evidence of malignancy. Given the patient’s previous cancer history and the occurrence of cancer in close relatives, genetic testing of peripheral blood was performed, which revealed the diagnosis of Lynch syndrome. Furthermore, the variant responsible for Lynch syndrome was found to be a mutation of NM_000251.3:c.211 + 1G > C in MSH2.
Literature
1.
go back to reference Yasuda S, Harada S, Tsujimoto A et al (2019) A pathological complete response by chemotherapy with S-1 and oxaliplatin for a locally advanced duodenal adenocarcinoma in Lynch syndrome: a case report. Surg case Rep 5(1):146CrossRefPubMedPubMedCentral Yasuda S, Harada S, Tsujimoto A et al (2019) A pathological complete response by chemotherapy with S-1 and oxaliplatin for a locally advanced duodenal adenocarcinoma in Lynch syndrome: a case report. Surg case Rep 5(1):146CrossRefPubMedPubMedCentral
2.
go back to reference Nishikawa Y, Hoshino N, Horimatsu T et al (2020) Chemotherapy for patients with unresectable or metastatic small bowel adenocarcinoma: a systematic review. Int J Clin Oncol 25(8):1441–1449CrossRefPubMed Nishikawa Y, Hoshino N, Horimatsu T et al (2020) Chemotherapy for patients with unresectable or metastatic small bowel adenocarcinoma: a systematic review. Int J Clin Oncol 25(8):1441–1449CrossRefPubMed
3.
go back to reference Hirashita T, Ohta M, Tada K et al (2018) Prognostic factors of non-ampullary duodenal adenocarcinoma. Jpn J Clin Oncol 48(8):743–747CrossRefPubMed Hirashita T, Ohta M, Tada K et al (2018) Prognostic factors of non-ampullary duodenal adenocarcinoma. Jpn J Clin Oncol 48(8):743–747CrossRefPubMed
4.
go back to reference Alicia L, Preethi S, Yelena K et al (2019) Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 37(4):286–295CrossRef Alicia L, Preethi S, Yelena K et al (2019) Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 37(4):286–295CrossRef
5.
go back to reference Akagi K, Oki E, Taniguchi H et al (2021) Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112(3):1105–1113CrossRefPubMedPubMedCentral Akagi K, Oki E, Taniguchi H et al (2021) Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112(3):1105–1113CrossRefPubMedPubMedCentral
6.
go back to reference Maio M, Ascierto PA, Mnzyuk L et al (2022) Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: update analysis from the phase II KEYNOTE-158 study. Ann Oncol 33(9):929–938CrossRefPubMed Maio M, Ascierto PA, Mnzyuk L et al (2022) Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: update analysis from the phase II KEYNOTE-158 study. Ann Oncol 33(9):929–938CrossRefPubMed
7.
go back to reference Goldstein J, Tran B, Ensor J et al (2014) Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032–1038CrossRefPubMedPubMedCentral Goldstein J, Tran B, Ensor J et al (2014) Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032–1038CrossRefPubMedPubMedCentral
8.
go back to reference Aurelien M, Dung T, Paolo AA et al (2020) Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38(1):1–10CrossRef Aurelien M, Dung T, Paolo AA et al (2020) Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38(1):1–10CrossRef
9.
go back to reference Laura LM, Anna JA, Jacov KB et al (2018) Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 25(9):2681–2692CrossRef Laura LM, Anna JA, Jacov KB et al (2018) Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 25(9):2681–2692CrossRef
10.
go back to reference Jabbour SK, Mulvihill D (2014) Defining the role of adjuvant therapy: ampullary and duodenal adenocarcinoma. Semin Radiat Oncol 24(2):85–93CrossRefPubMed Jabbour SK, Mulvihill D (2014) Defining the role of adjuvant therapy: ampullary and duodenal adenocarcinoma. Semin Radiat Oncol 24(2):85–93CrossRefPubMed
11.
go back to reference Kaklamanos IG, Bathe OF, Franceschi D et al (2000) Extent of resection in the management of duodenal adenocarcinoma. Am J Surg 179(1):37–41CrossRefPubMed Kaklamanos IG, Bathe OF, Franceschi D et al (2000) Extent of resection in the management of duodenal adenocarcinoma. Am J Surg 179(1):37–41CrossRefPubMed
12.
go back to reference Edwin OO, Sarah YB, Michael GS et al (2012) Neoadjuvant Treatment of Duodenal Adenocarcinoma: A Rescue Strategy. J Gastrointest Surg 16(2):320–324CrossRef Edwin OO, Sarah YB, Michael GS et al (2012) Neoadjuvant Treatment of Duodenal Adenocarcinoma: A Rescue Strategy. J Gastrointest Surg 16(2):320–324CrossRef
13.
go back to reference Christina T, Lars HJ, Maria R et al (2021) An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome. Clin Exp Gastroenterol 14:181–197CrossRef Christina T, Lars HJ, Maria R et al (2021) An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome. Clin Exp Gastroenterol 14:181–197CrossRef
14.
go back to reference Jan JK, Jan HK, Hans FA (2008) Small-bowel cancer in Lynch syndrome: is it time for surveillance? Lancet Oncol 9(9):901–905CrossRef Jan JK, Jan HK, Hans FA (2008) Small-bowel cancer in Lynch syndrome: is it time for surveillance? Lancet Oncol 9(9):901–905CrossRef
15.
go back to reference Nassim H, Marion D, Stanislas C et al (2019) Duodenal tumor risk in Lynch syndrome. Dig Liver Dis 51(2):299–303CrossRef Nassim H, Marion D, Stanislas C et al (2019) Duodenal tumor risk in Lynch syndrome. Dig Liver Dis 51(2):299–303CrossRef
16.
go back to reference Naruse H, Ikawa N, Yamaguchi K et al (2009) Determination of splice-site mutation in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay. Fam Cancer 8(4):509–517CrossRefPubMed Naruse H, Ikawa N, Yamaguchi K et al (2009) Determination of splice-site mutation in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay. Fam Cancer 8(4):509–517CrossRefPubMed
18.
go back to reference Jorg T, Sebastian S, Oliver H et al (2021) Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Oncologist 26(12):e2110–e2114CrossRef Jorg T, Sebastian S, Oliver H et al (2021) Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Oncologist 26(12):e2110–e2114CrossRef
Metadata
Title
A pathological complete response after immunotherapy with pembrolizumab for distal duodenal adenocarcinoma caused by Lynch syndrome: a case report
Authors
Shinichiro Ikeda
Qingjiang Hu
Keita Natsugoe
Tomoya Harima
Yasushi Tanaka
Izumi Kinoshita
Kentaro Nonaka
Sho Nambara
Ryota Nakanishi
Tomonori Nakanoko
Mitsuhiko Ota
Yasue Kimura
Eiji Oki
Yoshinao Oda
Tomoharu Yoshizumi
Publication date
26-07-2023
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal / Issue 4/2023
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-023-00622-w

Other articles of this Issue 4/2023

International Cancer Conference Journal 4/2023 Go to the issue